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JoBackground: Left ventricular (LV) hypertrophy is a risk
factor for cardiovascular death, but the genetic factors
determining LV size and predisposition to hypertrophy are
not well understood. We have previously linked the
quantitative trait locus cardiac mass 22 (Cm22) on
chromosome 2 with cardiac hypertrophy independent of
blood pressure in the spontaneously hypertensive rat. From
an original cross of spontaneously hypertensive rat with
F344 rats, we derived a normotensive polygenic model of
spontaneous cardiac hypertrophy, the hypertrophic heart
rat (HHR) and its control strain, the normal heart rat (NHR).
Methods and results: To identify the genes and
molecular mechanisms underlying spontaneous LV
hypertrophy we sequenced the HHR genome with special
focus on quantitative trait locus Cm22. For correlative
analyses of function, we measured global RNA transcripts
in LV of neonatal HHR and NHR and 198 neonatal rats of
an HHRNHR F2 crossbred population. Only one gene
within locus Cm22 was differentially expressed in the
parental generation: tripartite motif-containing 55
(Trim55), with mRNA downregulation in HHR (P<0.05)
and reduced protein expression. Trim55 mRNA levels were
negatively correlated with LV mass in the F2 cross
(r¼0.16, P¼0.025). In exon nine of Trim55 in HHR, we
found one missense mutation that functionally alters
protein structure. This mutation was strongly associated
with Trim55 mRNA expression in F2 rats (F¼10.35,
P<0.0001). Similarly, in humans, we found reduced
Trim55 expression in hearts of subjects with idiopathic
dilated cardiomyopathy.
Conclusion: Our study suggests that the Trim55 gene,
located in Cm22, is a novel candidate gene for polygenic
LV hypertrophy independent of blood pressure.
Keywords: animal models, cardiomyopathy, functional
genomics, microarray, transcriptome
Abbreviations: ABC transporters, adenosine triphosphate-
binding cassette transporters; BWA, Burrows–Wheeler
Aligner; CNV, copy number variation; Cm22, cardiac mass
22; CWI, cardiac weight index; GEO, gene expression
omnibus; HHR, hypertrophic heart rat; InDel, insertion and
deletion; LV, left ventricular; NHR, normal heart rat; qPCR,urnal of Hypertensionreal-time quantitative PCR; QTL, quantitative trait locus;
SHR, spontaneously hypertensive rat; SNP, single
nucleotide polymorphism; Trim55, tripartite motif-
containing 55INTRODUCTIONE
vidence for genetic determination of cardiac size
comes from numerous twin and family studies, in
which the heritability for cardiac mass has been
estimated to be 30–84% [1–3]. Cardiac hypertrophy, in
particular left ventricular (LV) hypertrophy, is the main
predisposition factor to cardiovascular disease outcomes
after age [4]. The molecular processes leading to an increase
in cardiac size independent of blood pressure are
still unknown.
The hypertrophic heart rat (HHR), a normotensive poly-
genic model of cardiac hypertrophy, is a unique model
because it permits the study of cardiac mass without the
confounding effects of high blood pressure. This model and
its control, the normal heart rat (NHR), were derived from
selectively crossing the spontaneously hypertensive rat
(SHR) and Fisher 344 rats for over 13 generations [5]. At
2 days old, the HHR have smaller hearts with fewer and
smaller cells when compared with the NHR defining hyper-
trophy later in life. By 12 weeks of age, however, the HHR
presents established LV hypertrophy, which leads toDOI:10.1097/HJH.0000000000000875
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Prestes et al.premature death because of heart failure as early as 48
weeks of age [5,6].
Studies that identify genetic factors contributing to LV
hypertrophy independent of pressure overload are crucial
to understand the molecular mechanisms involved. The
whole-genome sequencing of rat strains displaying diverse
phenotypes [7,8] and the creation of the Rat Genome Data-
base [9] permitted the discovery of a greater number of
allelic variants among rat strains. These data, associated
with gene expression studies, could identify disease-associ-
ated candidate genes [10]. Here, we aimed to take
advantage of the HHR as a unique model of polygenic
cardiac hypertrophy to investigate mutations in genes con-
tributing to this condition.
In this study, we compared the whole-genome sequence
of the HHR with the NHR and the reference laboratory rat,
Rattus norvegicus. We focused particularly on a region of
rat chromosome 2 that we identified in previous crosses of
the SHR and Wistar Kyoto rats as linked with LV mass
independent of blood pressure [11,12]. We originally des-
ignated this quantitative trait locus (QTL) as Lvm1, but it has
been subsequently labelled as cardiac mass 22 (Cm22). To
identify functional candidates in Cm22, we correlated
sequence and expression data in HHR and NHR and tested
their linkage with the LV mass phenotype in an F2 cross of
the HHR and NHR.
MATERIALS ANDMETHODS
Samples and tissue collection
Two-day-old HHR (n¼ 8 for arrays and n¼ 8 for follow-up
studies) and NHR (n¼ 8 for arrays and n¼ 9 for follow-up
studies) were euthanized by decapitation; and 13 (n¼ 10
HHR and n¼ 11 NHR) and 33-week old (n¼ 7 HHR and
n¼ 9 NHR) were euthanized with an overdose of pento-
barbitone (Lethabarb; Vet N-Pet Direct, Brisbane, Aus-
tralia). We crossed four male HHRs with four female
NHRs to produce an F1 population (n¼ 9). By crossing
male and female F1 rats we derived an HHRNHR F2
population (n¼ 198). F2 animals were euthanized by
decapitation at 2 days of age. Hearts were immediately
removed, and LV dissected from the atria. Cardiac weight
index (CWI, mg/g) was calculated from the total heart
weight (mg) relative to total body weight (g) of the animal
(Table S1, http://links.lww.com/HJH/A588; Figure S1,
http://links.lww.com/HJH/A588). Tissues were first pre-
served in liquid nitrogen and later transferred to a 808C
freezer. The study was approved by the Animal Ethics
Committees of the University of Melbourne and Deakin
University, and ratified at Federation University Australia.
DNA and RNA extraction
DNA from LV tissue was extracted using the PureLink
Genomic Extraction kit (Life Technologies, Carlsbad, Cal-
ifornia, USA). RNA was extracted using the miRNeasy kit
(Qiagen, Hilden, Germany). Both RNA and DNA were
quantified by spectrophotometry using a NanoDrop ND-
100 spectrophotometer (Thermo Scientific, Wilmington,
Delaware, USA). RNA used inmicroarrays was also assessed
for quality based on a RNA integrity number higher than
8 by electrophoresis in a 2100 Bioanalyzer (Agilent,2 www.jhypertension.comWaldbronn, Germany). Figure S2, http://links.lww.com/
HJH/A588, outlines the data analysis we used to identify
a new candidate gene for polygenic LV hypertrophy.
Whole-genome sequencing and analysis
Three male 13-week-old NHR and three age-matched HHR
(with established LV hypertrophy) were selected for whole-
genome sequencing. DNA concentration and quantity were
determined by Qubit Fluorometer (Life Technologies) and
integrity was determined by agarose gel electrophoresis.
The Illumina Cluster Station and Illumina HiSeq 2000 (San
Diego, California, USA) were used for preparation of
paired-end libraries with insert size of 500 bp. The
whole-genome sequencing was performed on the Illumina
HiSeq 2000 platform, where the sequences of each indi-
vidual were generated as 90 bp paired-end reads. Quality
filtered FASTQ paired-end sequences were mapped to the
Brown Norway reference genome Rnor_5.0 from March
2012 (Rat Genome Sequencing Consortium, RGSC v5.0)
using the Burrows–Wheeler Aligner (BWA-0.7.5a) software
[13]. Preprocessing for sorting and removal of duplicates
was performed using Picard tools [14]. We used default
parameters for the BWA-maximal exact match algorithm to
map reads and the Genome Analysis Tool Kit (GATK 3.1_1)
[15] to analyze mapped sequences [8]. The sequences were
realigned around insertions and deletions (InDels) and
base quality scores were recalibrated for accurate base
quality. We used Genome Analysis Tool Kit best practices
[16] for variant calling analysis, to identify single nucleotide
polymorphisms (SNPs) and SnpEff software [17] for func-
tional annotation. Copy number variations (CNVs) were
identified using Varscan [18] by simultaneously comparing
reads counts, base quality, and allele frequency, and struc-
tural variants were identified using Seeksv to detect large
insertions, deletions, and inversions.
We developed an in-house database for the storage and
analysis of the variants identified in the genome sequenc-
ing. This database was used to identify the unique variants
in HHR and NHR. Change rate, defined as the frequency of
a substitution occurring in the genome, was calculated as
the ratio between the number of changes and the genome
region.
Whole-genome transcriptome and analysis
Affymetrix GeneChip Rat Gene 1.0 ST Arrays (Tokyo,
Japan) were used for transcriptome-wide gene expression
analysis. We analyzed eight neonatal HHR (four male, four
female) and eight NHR (four male, four female). Each
animal was considered an individual sample and no pool-
ing was performed. Briefly, mRNA was converted to single-
stranded DNA, labelled and hybridized to GeneChip Rat
Gene 1.0 ST Arrays, which analyze 27 342 gene transcripts
using 722 254 probe sets (on average 26 probes/gene),
according to the manufacturer’s instructions, and with
the assistance of the Ramaciotti Centre for Gene Function
Analysis (University of New South Wales, Sydney, Aus-
tralia). The data set obtained has been deposited in the
National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) database according to
Minimum Information About a Microarray Experiment
guidelines with series accession number GSE38607Volume 34  Number 1  Month 2016
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bjsxbiiaowmwozy&acc¼GSE38607).
Results from arrays were normalized using robust-multi-
array analysis. Differentially expressed genes were ident-
ified using a two-sample t-test in the Partek Genomics Suite
(version 6.6) and selected based on their false discovery
rate q-value less than 0.05.
Gene functional annotation analysis
Gene functional annotation analysis was performed using
the Database for Annotation, Visualization and Integrated
Discovery [19,20] to ask which Kyoto Encyclopedia of
Genes and Genomes pathways were enriched within the
1231 genes that contained nonsynonymous unique SNPs in
the hypertrophic strain.
Quantitative trait loci characterisation
We previously described the QTL Cm22, also known as
Lvm1, to be associated with LV hypertrophy independent of
blood pressure [11,12]. QTL Cm22 is located on rat chromo-
some 2, nucleotide 98 037 122–177 517 146 in RGSC v5.0
[21].
Real-time quantitative PCR for gene expression
analysis
First-strand complementary synthesis reaction was per-
formed using the High-Capacity cDNA Reverse Transcrip-
tion Kit (Life Technologies). Primers were specifically
designed around the most differentially expressed probe
in the transcript cluster of each gene using Primer3 [22] and
NCBI online tool Primer Blast. Primers were designed to
flank an exon–exon junction. Primers and conditions used
are shown in Table S2, http://links.lww.com/HJH/A588.
Amplification reactions used the SensiFast SYBR Low-ROX
Kit qPCR reagent system (Bioline, Foster City, California,
USA) in a Viia7 qPCR instrument (Life Technologies).
Samples were run in duplicates. The specificity of the qPCR
was ensured by melting curve analysis and electrophoresis
in agarose gels (data not shown). The glyceraldehyde
3-phosphate dehydrogenase (Gapdh) was used as refer-
ence transcript. Significance was assessed by 2DDCT [23].
Protein measurements of tripartite
motif-containing 55 by western blot
Whole soluble protein was extracted from left ventricle of
13-week-old HHR and NHR using radioimmunoprecipita-
tion assay buffer (Sigma-Aldrich, Saint Louis, Missouri, USA)
and 1% Halt Protease and Phosphatase Inhibitor Cocktail
(Life Technologies, Rockford, Illinois, USA). One hundred
micrograms of extracted rat protein were resolved by
4–15%Mini-PROTEAN TGX Precast Gel (BioRad, Hercules,
California, USA) then electroblotted on to a Nitrocellulose
Membrane (Life Technologies). Membranes were blocked
for one hour at room temperature in 5% skim milk in Tris-
buffered saline (TBS)-Tween 20, then incubated overnight
at 4oC with antitripartite motif-containing 55 (anti-TRIM55)
(N-terminal) Rabbit Polyclonal antibody (1 : 2500 dilution,
ABIN405554, Antibodies-online Inc., Atlanta, Georgia,
USA) in 0.5% skim milk/TBS-Tween 20. Membranes were
stripped using Restore Western Blot Stripping Buffer (Life
Technologies) and probed with b-actin (1 : 5000 dilution,Journal of Hypertension3700, Cell Signalling, Danvers, Massachusetts, USA) in 0.5%
skim milk/TBS-Tween 20 solution for 1 h at room tempera-
ture, followed by four washing steps for 15min in TBS-
Tween 20 before detection using enhanced chemilumines-
cence SuperSignal West Pico Substrate (Life Technologies).
Images were captured with a UVITEC Alliance digital
imaging system (Thermo Scientific).
Three-dimensional protein prediction
The three-dimensional protein prediction of Trim55 of
HHR and NHR were generated after uploading the amino
acid sequences separately into online software Phyre [24],
using the normal modelling mode.
Statistical analyses
GraphPad Prism (version 6) package was used for graphing
and statistical analyses. Data sets were tested for normal
distribution using the D’Agostino and Pearson normality
test, and equal variances were analyzed using the F test. An
independent sample t test, Welch’s test, or Mann–Whitney
test were used to compare the data between the groups.
Significance was set at P less than 0.05. A one-way analysis
of variance (ANOVA) test was used to compare Trim55
abundance and exonic variant genotypes. A linear
regression test was performed to compare CWI and Trim55
abundance (Figure S3, http://links.lww.com/HJH/A588).
Gene expression in human hearts
We used data in the repository GEO series GSE1145 to
investigate the levels of TRIM55 in human idiopathic dilated
hearts (n¼ 11 control hearts and n¼ 15 idiopathic dilated
hearts). We then performed a whole-genome analysis using
the GEO tools to determine whether TRIM55 was overex-
pressed in human idiopathic dilated hearts.
RESULTS
Whole-genome sequencing
We sequenced thewhole-genome of the HHR and NHR and
separately compared each to the Brown Norway reference
genome (Rat Genome Sequencing Consortium, version
5.0). Postquality filtering was performed and duplicated
sequences produced by PCR amplification were removed.
Approximately 1.05 billion reads in the HHR and 977
million reads in the NHR were mapped to the Brown
Norway genome, resulting in over 77% genome coverage
and mean depth of whole-genome exceeding 25% for
each strain.
The comparative analysis revealed over 8 million var-
iants in the HHR and 7 million in the NHR (Fig. 1a and b)
relative to the Brown Norway reference genome. The
majority of these variants were SNPs – over 5.6 million
and 4.7 million in the HHR and NHR, respectively. To enrich
our comparison between the two genomes under investi-
gation, a comparison of the variants of the HHR to the NHR
was performed to identify those unique to either strain.
Unique variants represent 2.8 million and 1.7 million of the
HHR and NHR genome, respectively (Fig. 1c and d). In
contrast to the overall variant comparison, CNVs were the
most prevalent type of variants between HHR and NHR
strains.www.jhypertension.com 3
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FIGURE 1 Whole-genome sequencing analysis of variants. (a) All variants in the HHR and (b) the NHR. (c) Unique variants in the HHR and (d) NHR. CNV, copy number
variation; HHR, hypertrophic heart rat; InDel, insertions and deletions; NHR, normal heart rat; SNP, single nucleotide polymorphism.
TABLE 1. Classification of all single nucleotide polymorphisms
according to type and region in the genome
Genome region HHR NHR
30 UTR 14842 12251
50 UTR 2295 2031
Downstream 241403 203590
Frameshift coding – –
Intergenic 4 253 768 3554880
Intronic 1 352 486 1128853
Processed pseudogene 6066 5133
Pseudogene 39185 33264
Splice site, 30 UTR 21 16
Splice site, 50 UTR 34 25
Splice site, intronic 2731 2303
Splice site, nonsynonymous coding 410 369
Splice site, synonymous coding 484 411
Start codon gained 356 297
Start codon lost 16 14
Stop gained 319 258
Stop gained at splice site 11 5
Stop lost 19 19
Stop lost at splice site – –
Upstream 247516 209474
Within mature microRNA 18857 16332
Synonymous coding 22 826 18781
Nonsynonymous coding 19 033 16002
HHR, hypertrophic heart rat; NHR normal heart rat; UTR, untranslated region.
Prestes et al.We also investigated change rates in the HHR and NHR
genomes according to analyses of SNPs and InDels. Overall,
one variant is present in every 398 and 473 nucleotides in
the HHR and NHR, respectively. According to our analysis,
chromosome 20 and 12 have the highest change rate in the
HHR and NHR, respectively. Meanwhile, the X chromo-
some has the lowest change rate in both genomes (Table
S3, http://links.lww.com/HJH/A588).
We classified SNPs, insertions and deletions according to
zygosity (Table S4, http://links.lww.com/HJH/A588). As
expected, because of the inbred nature of both strains,
most SNPs and InDels are homozygous. In regards to
location, the majority of SNPs identified were intergenic,
and the SNPs located in genomic regions were mostly
present in introns in both genomes. Remarkably, no SNPs
caused a frameshift in a coding region or loss of stop codon
at a splice site (Table 1).
The SNPs located in coding regions were classified as
synonymous or nonsynonymous. In our study, these SNPs
were mostly synonymous not resulting in a change in the
amino acid sequence. Furthermore, we classified the
nonsynonymous SNPs into missense and nonsense. As
expected, most SNPs were missense in both strains
(Table S5, http://links.lww.com/HJH/A588).
Pathways associated with left ventricular
hypertrophy
Among the genes with unique SNPs in the HHR, there was a
significant overrepresentation of genes involved in adeno-
sine triphosphate-binding cassette (ABC) transporters
(rno02010), extracellular matrix-receptor interaction
(rno04512), and tryptophan metabolism (rno00380),
among others (Table S6, http://links.lww.com/HJH/A588).4 www.jhypertension.comQuantitative trait locus cardiac mass 22
We focused our gene expression and specific variants
analysis present within the QTL Cm22. The overall number
of variants and the unique variants were identified for each
strain in this QTL (Table 2) and those variants wereVolume 34  Number 1  Month 2016
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TABLE 2. Variants identified in the quantitative trait locus cardiac mass 22
All Unique
Type of variant HHR NHR HHR NHR
SNPs 182 404 153527 45731 16854
InDels 46 787 10038 15954 10038
HHR, hypertrophic heart rat; InDel, insertions and deletions; NHR normal heart rat; SNP, single nucleotide polymorphisms.
Tripartite motif-containing 55 in polygenic cardiac hypertrophyclassified according to their type and region in the genome
(Table 3).
The microarray data analysis showed that 109 genes
were significantly differentially expressed (fold change
>1.5) in the LV of neonatal HHR compared with neonatal
NHR. The only gene differentially expressed in Cm22 was
the gene for tripartite motif 55 (Trim55), being significantly
downregulated in our data set (1.52, adjusted P¼ 0.0045).
Array results were validated using qPCR in LV from 2-day,
13 and 33-week-old animals confirming that Trim55 was
downregulated in HHR from neonatal to late adulthood
(Fig. 2). Protein levels of Trim55, measured by western
blot, were also lower in HHR than NHR (Fig. 3) in LV of
13-week-old animals.
To identify possible variant targets that could contribute
to the hypertrophic phenotype, we explored unique var-
iants found in the Trim55 gene region (Chr2: 124 140 061–
124 182 032) in addition to its upstream and downstream
regions (Table 4). Our most significant finding was the
exonic SNP present in the HHR. This exonic SNP is found in
nucleotide position 124 181 039 of chromosome 2 (RGSC
v5.0). This nonsynonymous variant leads to a missense
mutation (C>T), resulting in a codon change (Ccc>Tcc)
Tcc) and, therefore, a change from a proline to serine in
the amino acid position 513 (P513S). In-silico proteinTABLE 3. Single nucleotide polymorphisms in the quantitative trait lo
All
Genome region HHR
30 UTR 305
50 UTR 46
Downstream 3815
Frameshift coding –
Intergenic 148 512
Intronic 32 686
Processed pseudogene 62
Pseudogene 948
Splice site, 30 UTR –
Splice site, 50 UTR 1
Splice site, intronic 43
Splice site, nonsynonymous coding 8
Splice site, synonymous coding 6
Start codon gained 8
Start codon lost –
Stop gained 6
Stop gained at splice site –
Stop lost –
Stop lost at splice site –
Upstream 3979
Within mature microRNA 372
Synonymous coding 384
Nonsynonymous coding 404
HHR, hypertrophic heart rat; NHR normal heart rat; UTR, untranslated region.
Journal of Hypertensionmodelling suggested this variant would lead to a change
in the predicted three-dimensional protein structure
(Fig. 4).
Trim55 mRNA levels were negatively correlated with LV
mass in the F2 cross (r¼0.16, P¼ 0.025) at neonatal age.
Although not statistically significant, Trim55 mRNA abun-
dance was also negatively correlated with CWI at 2 days
(r¼0.13, P¼ 0.05), 13 weeks (r¼1.04, P¼ 0.09) and 33
weeks old (r¼0.74, P¼ 0.07) (Figure S3, http://link-
s.lww.com/HJH/A588). We also found that the DNA
sequence variant (P513S) was strongly associated with
Trim55 abundance (F¼ 10.35, P< 0.0001) (Fig. 5). The
allele from the HHRwas associated with a lower expression
of Trim55 in the F2 rats, consistent with the association
observed in the parental strains.
Finally, we investigated the expression of TRIM55mRNA
in human idiopathic dilated hearts. In these hearts, we
found that the expression of TRIM55 was significantly
downregulated compared with control hearts (1.5,
P¼ 0.02; Fig. 2d).
DISCUSSION
Our combined sequencing and expression analyses
of the QTL Cm22, which we previously discovered oncus cardiac mass 22 classified by type and region of the genome
Unique
NHR HHR NHR
254 60 9
40 11 5
3296 853 334
– – –
124158 38712 14358
28288 5896 2416
47 21 6
816 304 172
– – –
1 – –
38 6 1
6 2 –
5 1 –
7 2 1
– – –
4 2 –
– – –
– – –
– – –
3533 871 425
256 146 30
328 79 23
372 73 41
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FIGURE 2 Trim55 mRNA expression in the hypertrophic heart rat (HHR), normal heart rat (NHR), and human hearts. Trim55 is downregulated in (a) neonatal, (b) 13-week-
old, (c) 33-week-old animals, and (d) human idiopathic dilated hearts. Graphs represent mean and error bars represent standard error. P<0.05, P<0.01, P<0.001.
Trim55, tripartite motif-containing 55.
Prestes et al.chromosome 2, identified the gene encoding Trim55 (alias
MuRF2) as a functional candidate for cardiac hypertrophy.
We discovered an exonic variant in Trim55 that is strongly
associatedwith Trim55 gene expression in the HHR and the
HHRNHR F2 population. This variant was also associated
with reduced Trim55 protein levels in the heart and the in-
silico analysis predicted that the resultant amino acid
change would alter protein folding. Furthermore, we have
found that Trim55 mRNA levels were reduced in the
hearts from patients with human idiopathic dilated cardio-
myopathy.
Our primary goal in this study was to delineate the
genetic factors that program the characteristics of the heart
in neonatal HHR that predisposes to adult hypertrophy. The
clue to the origins of the hypertrophy was our previous
discovery of reduced numbers of cardiomyocytes in the
adult HHR [6]. Importantly, we found that soon after birth
(neonates) HHR hearts tend to be smaller than NHR and
possess fewer cardiomyocytes [6]. Around 6–10 weeks of
age (at the age of reproductive maturity) cardiacNHR HHR
Trim55
Actb
60 kDa
50 kDa
27 kDa
FIGURE 3 Representative western blot analysis showing protein levels of tripartite
motif-containing 55 (Trim55) in the left ventricle of the hypertrophic heart rat
(HHR) and the normal heart rat (NHR) at 13 weeks of age.
6 www.jhypertension.comhypertrophy begins to become apparent in the HHR hearts
to become clearly established in adulthood. The implica-
tions of starting life with fewer cardiomyocytes are far
reaching, as the loss of ability to replicate after the neonatal
period (switch from proliferative to hypertrophic cellular
growth) means that the deficit in cell numbers cannot be
restored [25]. HHR hearts entering adolescence with fewer
cardiomyocytes are less able to cope with the considerable
physiological stresses of body growth (volume and pres-
sure loads). Individual cells must hypertrophy rapidly not
only to make up for missing cells but also for the relative
reduction in contractile efficiency that often accompanies
such hypertrophy. This exaggerated hypertrophy results in
a bigger heart than normal in relation to body size after
sexual maturity. In our study, we find Trim55 as a primary
candidate for the neonatal programming that predeter-
mines adult cardiac hypertrophy and eventual failure
in HHR.TABLE 4. Genomic region of variants in Trim55 unique to each
rat strain
Type of variant Genomic region HHR NHR
Upstream 0 0
Exonic 1 0
SNP Intronic 8 0
Downstream 1 0
Upstream 3 1
InDel Exonic 0 0
Intronic 7 12
Downstream 0 2
HHR, hypertrophic heart rat; InDel, insertions and deletions; NHR normal heart rat; SNP,
single nucleotide polymorphisms.
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NHR HHR
(a) (b)
FIGURE 4 In-silico three-dimensional modelling of Trim55 protein structure. (a) The predicted structure in the normal protein sequence and (b) including exonic SNP variant
present in the HHR sequence using online software Phyre. A predicted change in the protein domain is circled in red. HHR, hypertrophic heart rat; NHR, normal heart rat;
SNP, single nucleotide polymorphism; Trim55, tripartite motif-containing 55.
Tripartite motif-containing 55 in polygenic cardiac hypertrophyTrim55 and the cognate gene Trim63 (alias MuRF1)
encode striated muscle-specific proteins, which are local-
ized at the sarcomere M-line [26] – the site of myosin
crosslinking attachment at the titin C-terminal. This sarco-
mere region is understood to be of key importance in the
transduction of sarcomeric mechanical stress. Trim55 and
Trim63 are members of a subfamily of the really interesting
new gene-finger E3 ubiquitin ligases involved in mediating
replacement turnover of sarcomeric proteins via proteoso-
mal degradation [27]. Thus, altered regulation of Trim55
coding could be implicated in impaired sarcomeric protein
turnover as a trigger for the hypertrophic growth response
[28]. Trim55 knockout mice display severe diabetic cardi-
omyopathy characterized by early onset systolic dysfunc-
tion, higher LV mass, and increased heart weight when
compared with wild-type littermates [29]. Moreover, neo-
natal Trim55/Trim63 double knockout mice have severe
LV hypertrophy and high mortality rate after birth [30].
Trim63 was not differentially expressed in our data set
and variants were not present (data not shown). However,
the presence of a variant in the Trim55 coding region
leading to a change in the amino acid and protein sequence
causing a change in the three-dimensional protein structure
could influence the protein–protein interaction of Trim558
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FIGURE 5 Trim55 abundance in 2-day-old rats from the HHRNHR F2 population
according to exonic variant genotype. Graphs represent mean and error bars
represent standard error. HHR, hypertrophic heart rat; NHR, normal heart rat;
Trim55, tripartite motif-containing 55. F¼10.35, P<0.0001.
Journal of Hypertensionand Trim63 causing a disarray in the sarcomere assembly of
cardiac muscle cells, as previously suggested [28]. Further-
more, the prevalence of variants in TRIM55 and TRIM63 is
higher in patients with LV hypertrophy than in healthy
controls and could contribute to increased risk of LV hyper-
trophy [26].
This study is the first to describe genomic variation in a
model of spontaneous cardiac hypertrophy, the HHR, and
revealed many potential variants associated with cardiac
mass independent of blood pressure that included SNPs,
CNVs, and InDels.
The HHR strain carried a larger number of variants
relative to the NHR strain. Both genomes, however, carried
more SNPs and InDels than either of their parental strains,
the SHR and Fischer 344 (approximately 3.8 million SNPs
and 1.2 million InDels, and 3.4 million SNPs and 1.1 million
InDels, respectively) [7,8]. In this context, the identification
of unique variants to the HHR strain could assist the dis-
covery of genetic variants, and therefore, candidate genes
leading to the hypertrophic phenotype. Moreover, variants
unique to NHR could present a protection or compensatory
mechanism maintaining the normal phenotype.
Surprisingly, the frequency of variants is not uniform
throughout the genome, and appeared to show no relation
to chromosome size (Table S3, http://links.lww.com/HJH/
A588). Chromosome 1, the largest rat chromosome, had the
third largest change rate in the HHR and the seventh in the
NHR. In contrast, the seventh largest rat chromosome, the X
chromosome, had the largest change rate in both strains.
These findings indicate a possible hotspot for mutations in
the HHR that could contribute to the development of
cardiac disease.
SNPs comprise the largest source of genetic variability in
both humans and rats. The location and type of a SNP can
differently affect gene expression and lead to diseases and
phenotypical changes [31]. Nonsynonymous SNPs in an
exon affect the amino acid and, consequently, the protein
sequence and are believed to lead to the highest pheno-
typical changes in any genome [31,32]. Meanwhile, intronic
and synonymous SNPs do not affect the amino acid
sequence of a gene but could interfere with the splicing
site region making site recognition difficult [33,34] or affect
gene and protein expression by changing the shape of the
mRNA hindering its interaction with the ribosome [35]. The
intronic SNPs present in the Trim55 could be hinderingwww.jhypertension.com 7
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Prestes et al.the recognition of a splice site, which may influence mRNA
levels of this gene.
Apart from our Trim55 findings, our gene functional
annotation analysis identified the ABC transporters path-
way with the highest fold enrichment in our gene set. ABC
transporters are membrane proteins involved in energy-
dependant transport of substrates across biologic mem-
branes [27]. Mutations in its components have been pre-
viously described to cause dilated cardiomyopathy in
humans [36]. Moreover, other enriched pathways in our
dataset (e.g. extracellular matrix remodelling, tryptophan
metabolism, and lysosomal compartments) have also been
associated with cardiac disease and remodelling [37–39].
Nonsynonymous mutations in genes from these pathways
may be influencing the LV hypertrophy observed in the
HHR.
The study has some limitations. It would be preferable to
sequence a larger number of samples of each strain. Other
studies with similar design, however, have also analyzed
only one sample per strain [40]. Moreover, microarrays were
analyzed in neonatal heart, before LV hypertrophy is estab-
lished. The analyses of microarrays in hearts from animals
after the development of LV hypertrophy could identify
other genes in the QTL Cm22 differentially expressed with
relevant function in this condition.
In conclusion, we have characterized unique variants
present in the genome and identified Trim55 as a candidate
gene contributing to LV hypertrophy. Furthermore, we
identified Trim55 in the QTL Cm22 as differentially
expressed in LV hypertrophy in both model and humans
rendering a novel candidate gene for polygenic LV hyper-
trophy independent of blood pressure.
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194:1017–1028.Reviewers’ Summary Evaluations
Reviewer 1
Cardiac hypertrophy, in particular left ventricular (LV)
hypertrophy, is a risk factor for cardiovascular death, but
the genetic factors determining LV size and predisposition
to hypertrophy are not well understood. In this study, the
authors found that Trim55 gene, located in Cm22, is a novel
candidate gene for polygenic LV hypertrophy independent
of blood pressure. This finding will be helpful both in
clinical and basic research. In the future, the authors should
focus on the molecular mechanism of Trim55 in the devel-
opment of LV hypertrophy.Reviewer 2
Left ventricular hypertrophy is a risk factor for cardiovas-
cular death. However, the genetic factors that contribute to
cardiac hypertrophy are not well understood. The paper by
Prestes et al. identifies Trim55 as a functional candidate for
spontaneous cardiac hypertrophy in the rat locus Cm22.
Generally, the strength of the manuscript comes from its
strong genetic data support. One minor concern is that
many of genetic data were collected from neonate rats.
Furthermore, selective Trim55 genemanipulation in cardio-
myocytes will be recommended to test if this gene is
functionally related to cardiomyopathy in cardiovascular
diseases in future studies.www.jhypertension.com 9
